ParkinsonFranceV1, Main, Exploration, bibRecord, 003B89

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease

Identifieur interne : 003B89 ( Main/Exploration ); précédent : 003B88; suivant : 003B90

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease

Auteurs : H. Allain [France] ; A. Destee [France] ; H. Petit [France] ; M. Patay [France] ; S. Schück [France] ; D. Bentue-Ferrer [France] ; P. Le Cavorzin [France]

Source :

European neurology [ 0014-3022 ] ; 2000.

RBID : Pascal:00-0384587

Descripteurs français

Pascal (Inist)
- Parkinson maladie, De novo, Lévodopa, Chimiothérapie, Antiparkinsonien, Lisuride, Stimulant dopaminergique, Agoniste, Récepteur dopaminergique, Phase initiale, Association médicamenteuse, Evolution, Etude comparative, Traitement, Protocole thérapeutique, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Agonist, Antiparkinson agent, Chemotherapy, Comparative study, De novo, Dopamine agonist, Dopamine receptor, Drug combination, Early phase, Evolution, Levodopa, Lisuride, Parkinson disease, Therapeutic protocol, Treatment.

Abstract

The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson's disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson's disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson's Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p <0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Longterm follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001330
to stream PascalFrancis, to step Curation: 000108
to stream PascalFrancis, to step Checkpoint: 001216
to stream Main, to step Merge: 004253
to stream Main, to step Curation: 003B89

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A." last="Destee">A. Destee</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique, Hôpital Roger Salengro</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petit, H" sort="Petit, H" uniqKey="Petit H" first="H." last="Petit">H. Petit</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique, Hôpital Roger Salengro</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patay, M" sort="Patay, M" uniqKey="Patay M" first="M." last="Patay">M. Patay</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratoire Schering S.A.</s1>
<s2>Lys-Les-Lannoy</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lys-Les-Lannoy</wicri:noRegion>
<wicri:noRegion>Laboratoire Schering S.A.</wicri:noRegion>
<wicri:noRegion>Laboratoire Schering S.A.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schuck, S" sort="Schuck, S" uniqKey="Schuck S" first="S." last="Schück">S. Schück</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Le Cavorzin, P" sort="Le Cavorzin, P" uniqKey="Le Cavorzin P" first="P." last="Le Cavorzin">P. Le Cavorzin</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0384587</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0384587 INIST</idno>
<idno type="RBID">Pascal:00-0384587</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001330</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000108</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001216</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001216</idno>
<idno type="wicri:doubleKey">0014-3022:2000:Allain H:five:year:follow</idno>
<idno type="wicri:Area/Main/Merge">004253</idno>
<idno type="wicri:Area/Main/Curation">003B89</idno>
<idno type="wicri:Area/Main/Exploration">003B89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A." last="Destee">A. Destee</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique, Hôpital Roger Salengro</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petit, H" sort="Petit, H" uniqKey="Petit H" first="H." last="Petit">H. Petit</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Clinique Neurologique, Hôpital Roger Salengro</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patay, M" sort="Patay, M" uniqKey="Patay M" first="M." last="Patay">M. Patay</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratoire Schering S.A.</s1>
<s2>Lys-Les-Lannoy</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lys-Les-Lannoy</wicri:noRegion>
<wicri:noRegion>Laboratoire Schering S.A.</wicri:noRegion>
<wicri:noRegion>Laboratoire Schering S.A.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schuck, S" sort="Schuck, S" uniqKey="Schuck S" first="S." last="Schück">S. Schück</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
<author><name sortKey="Le Cavorzin, P" sort="Le Cavorzin, P" uniqKey="Le Cavorzin P" first="P." last="Le Cavorzin">P. Le Cavorzin</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
<orgName type="university">Université de Rennes 1</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European neurology</title>
<title level="j" type="abbreviated">Eur. neurol.</title>
<idno type="ISSN">0014-3022</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European neurology</title>
<title level="j" type="abbreviated">Eur. neurol.</title>
<idno type="ISSN">0014-3022</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>De novo</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Drug combination</term>
<term>Early phase</term>
<term>Evolution</term>
<term>Levodopa</term>
<term>Lisuride</term>
<term>Parkinson disease</term>
<term>Therapeutic protocol</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>De novo</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Lisuride</term>
<term>Stimulant dopaminergique</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Phase initiale</term>
<term>Association médicamenteuse</term>
<term>Evolution</term>
<term>Etude comparative</term>
<term>Traitement</term>
<term>Protocole thérapeutique</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson's disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson's disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson's Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p <0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Longterm follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
<li>Région Bretagne</li>
</region>
<settlement><li>Lille</li>
<li>Rennes</li>
</settlement>
<orgName><li>Université de Rennes 1</li>
</orgName>
</list>
<tree><country name="France"><region name="Région Bretagne"><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</region>
<name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
<name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A." last="Destee">A. Destee</name>
<name sortKey="Le Cavorzin, P" sort="Le Cavorzin, P" uniqKey="Le Cavorzin P" first="P." last="Le Cavorzin">P. Le Cavorzin</name>
<name sortKey="Patay, M" sort="Patay, M" uniqKey="Patay M" first="M." last="Patay">M. Patay</name>
<name sortKey="Petit, H" sort="Petit, H" uniqKey="Petit H" first="H." last="Petit">H. Petit</name>
<name sortKey="Schuck, S" sort="Schuck, S" uniqKey="Schuck S" first="S." last="Schück">S. Schück</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:00-0384587
   |texte=   Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri